Skip to main content

Table 4 Therapeutic indicator of global status: ΔCDR-SB

From: Cilostazol as an add-on therapy for patients with Alzheimer’s disease in Taiwan: a case control study

Therapeutic response, N (%)

Favorablea,22 (37.9)

Poorb,36 (62.1)

p-value

Age, years (mean ± SD)

82.1 ± 6.2

82.7 ± 5.3

0.741

Education, years (mean ± SD)

7.7 ± 5.1

7.9 ± 4.6

0.888

Gender, female (%)

14 (63.6)

30 (83.3)

0.089

1st CDR-SB

8.8 ± 3.6

7.6 ± 3.2

0.207

1st MMSE

13.8 ± 6.7

14.9 ± 6.1

0.534

Cilostazol use

  

0.104

Yes

14 (48.3)

15 (51.7)

 

No

8 (27.6)

21 (72.4)

 

ApoE ε4(+),n (%)

6 (31.6)

6 (17.7)

0.245

  1. MMSE Mini-Mental Status Examination, CDR_SB Clinical Dementia Rating Sum of Boxes scale; ApoE apolipoprotein E, ΔCDR_SB: 2nd CDR_SB – 1st CDR_SB
  2. aΔCDR_SB ≤ 0
  3. bCDR_SB > 0